Menopause Treatment Market Size was valued at USD 10.8 Billion in 2023. The Menopause Treatment Market industry is projected to grow from USD 11.45 Billion in 2024 to USD 17.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.28% during the forecast period (2024 - 2032). Growing public knowledge of the benefits of hormone replacement treatment, as well as the rising prevalence of menopausal symptoms are the key market drivers enhancing the market growth.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
In January 2024, Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada. IMVEXXY® (estradiol vaginal inserts) is approved for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). VVA is a prevalent, chronic, and progressive condition associated with menopause. Common symptoms of VVA include dryness, discomfort, and pain in the vaginal and vulvar areas. IMVEXXY® is the only product in its therapeutic class that provides both four mcg or ten mcg doses of 17β estradiol; this means that it has been assigned the lowest effective dose among Health Canada-approved virginal estradiols.
In August 2023, Clearblue®, the world’s #1 selling brand in home pregnancy and fertility tests2, is expanding to a new category – menopause. Women in or approaching menopause are underserved consumers, as more than two in three women feel unprepared to take on their menopause journey3, and only 45% feel they have enough information to manage it4. In response, Clearblue® is turning up the volume on the menopause conversation by launching its new Clearblue® Menopause Stage Indicator, the first and only product to combine a woman’s urine FSH measurements with her age and cycle history to indicate her likely menopause stage. The Clearblue® Menopause Stage Indicator stores results safely on its free-to-download app5 Menopause Stage – Clearblue me®. The app determines her likely menopause stage by combining the results of five urine FSH tests with her cycle history and age.
In December 2023, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) on December 7 approved VEOZATM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause. Worldwide, more than half of women 40 to 64 years of age experience VMS, with rates in Europe ranging from 56% to 97%. The prevalence of moderate to severe VMS in postmenopausal women in Europe has been reported at 40%.6 VMS can have a disruptive impact on women's daily activities and overall quality of life.
Market CAGR for menopause treatment is being driven by the rising demand for non-hormonal treatments.. Many women are unable or reluctant to utilize hormone therapy due to worries about side effects or increased risk of certain health disorders, such as breast cancer. As a result, there is an increasing demand for non-hormonal treatments such as selective serotonin reuptake inhibitors (SSRIs), gabapentin, and cognitive behavioural therapy (CBT). Non-pharmacologic treatments such as acupuncture and herbal supplements are also becoming increasingly popular. Non-hormonal therapies are projected to have increased demand in the coming years, owing to increased awareness of these treatment choices and a growing desire for individualized and integrative approaches to menopausal management. As a result, firms are investing in the development of new non-hormonal medicines, which is projected to drive additional expansion in this market sector.
Furthermore, the utilization of new medication delivery technologies for menopause treatment is growing. Transversal patches, vaginal rings, and subcutaneous implants, for example, have various advantages over standard oral medicines, including greater efficacy, safety, and patient compliance. These delivery systems enable a controlled release of hormones or other active substances, which can aid in the management of menopausal symptoms. Furthermore, they can lower the risk of side effects associated with oral medicines while also improving patient convenience.
Additionally, Effective therapy for menopause symptoms has become increasingly important in recent years, as women's physical and mental health has deteriorated. Hot flashes, formication, migraine, anxiety, exhaustion, mood swings, impatience, and insomnia have all become major difficulties around the world, driving players to devise novel and effective treatment approaches. Significant investments are being made in extended R&D operations to launch novel medications, which aids in the growth of the menopause therapy market. Women are increasingly leading hectic and demanding lives, leaving little time for peace of mind or relaxation, while a lack of sleep has exacerbated menopausal symptoms. This feature, along with rising female disposable income in various countries, has boosted the menopause treatment market.
Another factor fueling the growth of the menopause therapy market is the growing demand for personalized medicine. Personalized medicine refers to the customizing of medical therapy to each patient's unique features, such as genetic makeup, lifestyle, and medical history. As our understanding of the underlying causes of menopausal symptoms increases, there is a growing tendency toward the creation of individualized menopause treatments.
For example, Astellas Pharma Inc. and MBC Biolabs established collaboration in 2019 to investigate tailored treatments for menopausal symptoms. The cooperation aims to uncover innovative targets for menopause treatment and to develop individualized medicines based on the unique characteristics of each patient.
The Menopause Treatment Market segmentation, based on Treatment includes hormonal treatment, combination. The hormonal treatment has the biggest market share in the menopausal treatment market. Hormonal medications, such as estrogen therapy and combination therapy (estrogen plus progestin), are the most widely prescribed treatments for menopausal symptoms include hot flashes, night sweats, and vaginal dryness. Hormonal therapies operate by replenishing the low levels of estrogen and progesterone that occur after menopause.
The Menopause Treatment Market segmentation, based on distribution channel, includes hospital pharmacies, retail pharmacies and online stores. The retail pharmacies segment accounts for the majority of the menopause therapy market. This is the most popular distribution route for menopause treatments, and it comprises chain drug stores, mail-order pharmacies, and independent pharmacies. Consumers can easily access retail pharmacies, which offer a wide range of products such as prescription pharmaceuticals, over-the-counter medications, and dietary supplements. Many retail pharmacies also provide online ordering and home delivery, making it easier for women to get the therapies they require.
Figure1 Menopause Treatment Market, by Distribution channel, 2022&2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America is predicted to be the market's dominant region, because of the region's high prevalence of menopause and accompanying symptoms. Furthermore, the region has a well-established healthcare infrastructure, making menopause treatments more accessible to women. The availability of novel treatments and therapies, as well as a growing emphasis on women's health, are likely to drive the market in North America.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 MENOPAUSE TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Menopause Treatment Market accounts for the second-largest market share due of increased introduction of innovative medications by multiple significant stakeholders. Further, the German Menopause Treatment Market held the largest market share, and the UK Menopause Treatment Market was the fastest growing market in the European region
The Asia-Pacific Menopause Treatment Market is expected to grow at the fastest CAGR from 2024 to 2032. This is because women in the region are becoming more aware of menopause and its effects. Moreover, China’s Menopause Treatment Market held the largest market share, and the Indian Menopause Treatment Market was the fastest growing market in the Asia-Pacific region.
Menopause Treatment Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Menopause Treatment Market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Menopause Treatmentindustry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Menopause Treatment industry to benefit clients and increase the market sector. In recent years, the Menopause Treatment industry has offered some of the most significant advantages to medicine. Major players in the Menopause Treatment Market, including Novartis AG (Switzerland), Cipla Inc. (India),Teva Pharmaceuticals (Israel), Merck & Co. Inc. (US), Abbott Laboratories (US) and others, are attempting to increase market demand by investing in research and development operations.
Allergan plc is a pharmaceutical business based in the United States and Ireland that acquires, develops, manufactures, and markets brand-name pharmaceuticals and medical devices in the fields of medical aesthetics, eye care, central nervous system, and gastroenterology. Botox is manufactured by this company. Allergan plc was founded in March 2015 when Irish-registered Actavis plc acquired Allergan, Inc. and assumed the Allergan moniker. In 2019, Allergan plc announced the FDA clearance of a novel intrauterine device (IUS) for pregnancy prevention and heavy menstrual bleeding therapy. The IUS, known as Liletta, is designed to be placed into the uterus by a healthcare professional and contains levonorgestrel, a synthetic progestin.
Novo Nordisk A/S is a Danish multinational pharmaceutical corporation headquartered in Bagsvaerd, Denmark, with manufacturing sites in nine countries and affiliates or offices in five. Novo Nordisk is dominated by Novo Holdings A/S, which owns around 25% of the company's shares and a relative majority (45%) of its voting shares. Novo Nordisk is a pharmaceutical company that makes and sells diabetic drugs and equipment. Novo Nordisk also works on hemostasis, growth hormone therapy, and hormone replacement therapy. In September 2019, Novo Nordisk A/S has received FDA approval for a novel transdermal patch for the treatment of vasomotor symptoms associated with menopause. Minivelle is a low-dosage estradiol patch that gives a continuous dose of estradiol over a 3- to 4-day period. The patch is intended to be put to the skin of the abdomen, thigh, or buttocks.
Key Companies in the Menopause Treatment market include
Menopause Treatment Industry Developments
In May 2023, Astellas Pharma Inc. received FDA approval for the first of its kind nonhormonal neurokinin 3 (NK3) receptor antagonist called VEOZAH (fezolinetant) for treating moderate to severe vasomotor symptoms (VMS) caused due to menopause.
In March 2022, Amyris, Inc. acquired MenoLabs, LLC, a company focused on providing menopause treatment and undertaking research on the same area. This acquisition will help Amyris, Inc. expand its product portfolio for menopause treatments.
In March 2020, Bayer AG announced the acquisition of KaNDy Therapeutics, a leading provider of women healthcare products, including menopause treatments. The acquisition further strengthened its women’s healthcare product portfolio.
In April 2019, Amgen received FDA approval for EVENITY (romosozumab-aqqg) for the treatment of post-menopausal osteoporosis. Osteoporosis fractures are highly common in women, especially after menopause.
| Report Attribute/Metric | Details |
| Market Size2023 | USD 10.8 Billion |
| Market Size 2024 | USD 11.45 Billion |
| Market Size 2032 | USD 17.3 Billion |
| Compound Annual Growth Rate (CAGR) | 5.28% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Treatment, Distribution Channel, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Allergan (Ireland), Eli Lily and Company (US), Emcure Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc. (India),Teva Pharmaceuticals (Israel), Merck & Co. Inc. (US), Abbott Laboratories (US) |
| Key Market Opportunities | Menopausal Herbal Treatment |
| Key Market Dynamics | Menopausal Symptoms Are Increasing |
Menopause Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Menopause Treatment Market size was valued at USD 10.8 Billion in 2023.
Menopause treatment market valuation would be USD 17.3 Billion by 2032.
The market is projected to grow at a CAGR of 5.28% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Novartis AG (Switzerland), Cipla Inc. (India),Teva Pharmaceuticals (Israel), Merck & Co. Inc. (US), Abbott Laboratories (US).
The hormonal treatment category dominated the market in 2023.
The retail pharmacy had the largest share in the market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
